Brian Leaf

Cooley advised Adaptive Phage Therapeutics, a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX, a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.

Cooley advised Autolus – a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies – on its strategic collaboration with BioNTech, an immunotherapy company pioneering novel therapies for cancer and other serious diseases, to advance both companies’ autologous CAR-T programs toward commercialization, as well as a $350 million underwritten offering.

Cooley advised MaxCyte on its $201.8 million initial public offering of 15,525,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. MaxCyte, whose securities now trade on the Nasdaq Global Select Market under the symbol “MXCT,” also trades on the London Stock Exchange under the symbols "MXCT" and "MXCN." MaxCyte is a leading provider of cell-engineering platform technologies. Partners Christian Plaza, Brian Leaf and Claire Keast-Butler led the Cooley team.

Cooley advised the underwriters on Elevation Oncology’s $106.5 million initial public offering of 6,653,407 shares of common stock. J.P. Morgan Securities, Cowen and Company, and SVB Leerink acted as joint bookrunning managers for the offering. Wedbush PacGrow acted as lead manager for the offering. Elevation Oncology, whose securities now trade on the Nasdaq Global Select Market under the symbol ELEV, is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers. Partners Charlie Kim, Brian Leaf and Div Gupta led the Cooley team.